Table 1.

Histopathological characteristics of pre-treatment core biopsies and therapy-related data on the entire cohort of 506 patients with breast cancer treated with neoadjuvant chemotherapy

Histopathological data				Therapy-related data
	Number of cases	Total %	Valid %		Number of cases	Total %	Valid %
Grade				Response
1	35	6.9	7.3	Complete	133	26.3	27.1
2	247	48.8	51.7	Partial	283	55.9	57.8
3	196	38.7	41	Absent	74	14.6	15.1
Unknown	28	5.5		Unknown	16	3.2
ER score				Antracyclins
Positive	333	65.8	65.8	Yes	412	81.4	88.2
Negative	173	34.2	34.2	No	55	10.9	11.8
Unknown	0	0.0		Unknown	39	7.7
PGR score				Cyclophosphamide
Positive	280	55.3	55.4	Yes	347	68.6	73.5
Negative	225	44.5	44.6	No	125	24.7	26.2
Unknown	1	0.2		Unknown	34	6.7
PGR cut-off				Taxanes
<20 %	290	57.3	57.5	Yes	328	64.8	68.2
≥20 %	214	42.3	42.5	No	153	30.2	31.8
Unknown	2	0.4		Unknown	25	4.9
HER2 score				Herceptin
Positive	104	20.6	21	Yes	90	17,8	18.5
Negative	391	77.3	79	No	397	78.5	81.5
Unknown	11	2.2		Unknown	19	3.8
Lobular				5-FU
Yes	40	7.9	8	Yes	33	6,5	26.4
No	462	91.3	92	No	92	18.2	73.6
Unknown	4	0.8		Unknown	381	75.3
Inflammation				Vinca alkaloids
TILs present	258	51	74.1	Yes	15	3.0	3.8
TILs absent	90	17.8	25.9	No	381	75.3	96.2
Unknown	158	31.2		Unknown	110	21.7
Necrosis
Present	128	25.3	36.8
Absent	220	43.5	63.2
Unknown	158	31.2
Molecular categories*
Luminal A	70	13.8	14.8
Luminal B/HER2−	188	37.2	39.8
Luminal B/HER2+	46	9.1	9.7
Triple-negative	57	11.3	12.1
HER2+	111	21.9	23.5
Unknown	34	6.7

*following St. Gallen recommendations [1]